Recapping some news from the first day of the JP Morgan Healthcare Conference:
J&J’s agreement to acquire Intra-Cellular Therapies for $14.6B brings FDA-approved drug Caplyta to their line-up. Caplyta is forecasted to generate between $665M-$685M in 2024 sales
Teva Pharmaceutical Industries announced sales of $2.2B last year (doubling their 2022 numbers) for three major brands Austedo, Ajovy, and Uzedy (JPM Teva Deck)
Vertex announced positive views on potential FDA approval on January 30th of Suzetrigine and its potential “multi-billion dollar opportunity” (Vertex JPM Deck)
Moderna announced it is cutting 2025 sales guidance and is seeking to cut $1B in costs this year and $500B in 2026
Gilead announced their expectation to launch seven new HIV products before its flagship Biktarvy loses its market exclusivity in 2033
Incyte announced plans to launch four new drugs in 2025 (Incyte JPM Deck)
Комментарии